Horizon Discovery Inks Alliance with Agios Pharmaceuticals | GenomeWeb
NEW YORK (GenomeWeb News) – Horizon Discovery said today that it has signed two agreements with cancer startup Agios Pharmaceuticals related to its X-Man cell-line technology.
 
The Cambridge, UK-based firm said that it has licensed certain X-Man cell lines, including major cancer-causing genes and their matched normal genetic backgrounds. In addition, it said that it would screen a number of Agios lead compounds on a wide panel of genotypes.
 

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

Pacific Biosciences is hosting a competition in which researchers are vying to win free sequencing for an organism with the most interesting genome.

An opinion piece appearing in Newsday likens familial DNA searches to stop-and-frisk policies.

The San people of Africa have drawn up a code of conduct for researchers, according to the Conversation.

In Nature this week: genotypes linked to hip osteoarthritis, and more.